John Wagstaff
University of Siena
3 papers in the Anchorcite directory, published between 2015 and 2017, cited 19,700 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Cutaneous Melanoma Detection and Management · 2 papers
- Melanoma and MAPK Pathways · 2 papers
- Renal cell carcinoma treatment · 1 paper
- Ferroptosis and cancer prognosis · 1 paper
Frequent co-authors
- James Larkin · 3 papers
- Vanna Chiarion‐Sileni · 2 papers
- Rene C. Gonzalez · 2 papers
- Jean‐Jacques Grob · 2 papers
- Charles Lance Cowey · 2 papers
- Christopher D. Lao · 2 papers
- Dirk Schadendorf · 2 papers
- Reinhard Dummer · 2 papers
Papers
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…
Metadata from OpenAlex (CC0).